The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.
Rheum for Everyone, Deliberate Practice to Achieve Mastery, Episode 24 (video)
In this episode, Dr. Kumar talks about the fascinating and intriguing secret lives of rheumatologists—real life superheroes.
ACR Delegates Prepare for Fall Season Advocacy with the AMA
The ACR’s delegation to the American Medical Association’s House of Delegates is gearing up for the HOD Interim Meeting, slated for Nov. 14–18. Several members share their views on the value of this advocacy work and top issues this fall.
Coming Soon: Rheumatology Physician & Faculty Survey
Two upcoming surveys of ACR members will help identify trends and issues affecting academic and private practice rheumatology, as well as provide benchmarking data and inform advocacy efforts.
Urge Congress to Avoid Disruption to Telemedicine
Telehealth is at risk. Congress must act before the end of September to maintain vital flexibility and reimbursement for telemedicine services.
ACR’s Response to Proposed Physician Medicare Cuts Garners National Media Attention
ACR President Carol Langford, MD, MHS, is making headlines as a leading voice in the fight against proposed Medicare reimbursement cuts that threaten the sustainability of rheumatology practices and patient access to care.
Share Your Story: Help Shape the Future of Noncompete Agreements for Rheumatologists
The Federal Trade Commission is seeking input about the use and impacts of noncompete agreements, with particular interest in the healthcare sector. ACR/ARP members are encouraged to share your experiences about how such agreements have affected your career and patients.
AHIP Confirms Continued Coverage of ACIP-Recommended Vaccines Through End of 2026
All vaccines recommended by the CDC’s ACIP as of Sept. 1, 2025—including updated COVID-19 and influenza shots—will be covered by health plans with no cost sharing for patients through the end of 2026.
2024 Traditional MIPS & MVP Final Scores Now Available
MIPS-eligible clinicians should review their scores to confirm performance. Any scoring concerns can be addressed through a targeted review
Oral Treatment for PsA Inches Closer to FDA Approval
The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 833
- Next Page »